source
- Recent Lisata prize Marea touts ‘exciting’ lipid disorder phase 2 win, mulls obesity potentialFresh from a merger with oncology drugmaker Lisata Therapeutics, cardiometabolic biotech Marea Therapeutics has revealed results from the first part of a phase 2b study showing its drug candidate M…Fierce Biotech · 3d ago↗ source
- Novartis reports seven new tumor cases in children treated with Zolgensma gene therapyNovartis has disclosed that seven children who received its SMA gene therapy, Zolgensma, have been found to have tumors that were not previously reported. The cases were brought to light by an adv…